Foundation Launches Investment Fund to Speed Multiple Myeloma Treatments
The investment fund spun off from the Multiple Myeloma Research Foundation will start at $50 million and will be self-sustaining, focusing on early-stage biotech companies.
The Multiple Myeloma Research Foundation (MMRF)
In its statement, MMRF said the $50 million
MMRF president and chief executive officer
Peter Kosa, PhD, MBA, will be the first managing director of the new fund. Kosa will be part of a 7-member board of directors, including 4 who are on MMRF’s board. “The MMRF is an incredibly well-respected third-party organization, with a 20-year history of unparalleled progress in multiple myeloma and advanced models in both research and business,” Kosa said in the MMRF statement. “I am honored to work alongside them to expand our portfolio of assets and make new therapies available for patients.”
Founded in 1998, MMRF is well known for bringing a business approach to its investment in more than 75 clinical trials that have led to
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025
- Modest Reductions in PrEP Coverage Result in Avoidable HIV Infections
September 17th 2025